4.5 Article

Management of Pigmented Conjunctival Lesions

Journal

OCULAR SURFACE
Volume 10, Issue 4, Pages 251-263

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jtos.2012.08.002

Keywords

BRAF; complexion-associated melanosis; conjunctival melanosis; genetics; melanoma; nevus; no-touch surgery; ocular surface; pigmented lesion; primary acquired melanosis (PAM); topical chemotherapy

Categories

Funding

  1. NIH Center Core Grant [P30EY014801]
  2. Research to Prevent Blindness Unrestricted Grant
  3. Department of Defense (DOD) [W81XWH-09-1-0675]
  4. Ronald and Alicia Lepke Grant
  5. Jimmy and Gay Bryan Grant
  6. Hager Family Grant
  7. Max-Kade-Foundation, NY

Ask authors/readers for more resources

Pigmented conjunctival lesions primarily include melanoma, nevus, primary acquired melanosis (PAM), and complexion-associated melanosis. The incidence of conjunctival malignant melanoma (CMM) has significantly increased in the USA and Europe over the years, and it carries a very serious risk for metastasis and melanoma-related death. Conjunctival melanoma can arise de novo or from precursor lesions, nevus, and PAM. PAM is histologically separated into two distinct forms: PAM with atypia and without atypia. PAM with severe atypia progresses to malignant melanoma in up to 50% of cases and PAM without atypia virtually never progresses. Nevus is a benign melanocytic tumor that only rarely undergoes malignant transformation. Complexion-associated melanosis is frequently seen in more darkly pigmented individuals and does not progress to melanoma, although it can become very large. A detailed literature review on the various pigmented conjunctival lesions together with a schematic approach to diagnosis and management is presented.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available